

PAPAYER SOMNIFERUM L.: A COMPREHENSIVE REVIEW ON BOTANY, PHYTOCHEMISTRY, PHARMACOLOGY, TOXICOLOGY AND FUTURE PROSPECTS

Vennila V^{1*}, Gayathri K², Monisha B³, Nithiya S⁴, Darani V⁵, Baranika V⁶, Kowsiya M⁷, Anusuya M⁸

^{1*}Guest Lecturer, PG & Research Department of Biochemistry, D.G.Govt Arts College for Women, Mayiladuthurai, Tamilnadu, India.

Article Received on 01 Oct. 2025,
Article Revised on 21 October 2025,
Article Published on 01 Nov. 2025,
<https://doi.org/10.5281/zenodo.17473162>

*Corresponding Author

Dr. Vennila V

Guest Lecturer, PG & Research
Department of Biochemistry,
D.G.Govt Arts College for Women,
Mayiladuthurai, Tamilnadu, India.



How to cite this Article: Vennila V*, Gayathri K, Monisha B, Nithiya S, Darani V, Baranika V, Kowsiya M, Anusuya M, (2025). Papaver Somniferum L.: A Comprehensive Review On Botany, Phytochemistry, Pharmacology, Toxicology And Future Prospects World Journal of Pharmaceutical Research, 14(21), 332–343.

This work is licensed under Creative Commons Attribution 4.0 International license.

ABSTRACT

Papaver somniferum L. (opium poppy) is one of the oldest cultivated medicinal plants and remains indispensable in modern pharmacology due to its unique production of benzyl isoquinoline alkaloids such as morphine, codeine, thebaine, papaverine, and noscapine. These compounds possess potent analgesic, antitussive, antispasmodic, and antineoplastic properties. At the same time, the species is associated with profound challenges, including narcotic abuse, legal restrictions, and safety concerns. This review consolidates current knowledge on the botany, cultivation, phytochemistry, pharmacology, toxicology, ethnomedicine, genomics, and future prospects of *P. somniferum*. Emphasis is placed on biosynthetic pathways, pharmacological mechanisms, and regulatory implications. Although clinical evidence remains limited beyond opioid alkaloids, emerging research suggests novel therapeutic potential for non-narcotic constituents. The

duality of this plant—as both a life-saving pharmaceutical source and a substance of abuse—necessitates balanced approaches integrating phytochemical research, synthetic biology, regulatory vigilance, and evidence-based clinical trials.

KEYWORDS: *Papaver somniferum*, opium poppy, morphine, alkaloids, phytochemistry, pharmacology, toxicity, review.

INTRODUCTION

The opium poppy, *Papaver somniferum* L., is one of humanity's most significant medicinal plants. Its history stretches back more than 6,000 years, with archaeological evidence from the Mediterranean, Mesopotamia, and Indus Valley civilizations showing its cultivation and ritual use.^[1,2] In Sumerian records (c. 3400 BCE), opium was termed “Hul Gil,” meaning the “joy plant”.^[2] Later, in Greco-Roman medicine, physicians like Hippocrates and Dioscorides prescribed opium preparations for pain, sleep disorders, and diarrhea.^[3] By the Islamic Golden Age, Avicenna included opium in The Canon of Medicine, describing both therapeutic benefits and addictive dangers.

Modern pharmacology owes much of its development to the isolation of morphine from opium by Friedrich Serturmer in 1804, which marked the beginning of alkaloid chemistry.^[5,6] Since then, *P. somniferum* has remained central to medicine as a source of alkaloids like morphine (the “gold standard” analgesic), codeine (antitussive), papaverine (vasodilator), noscapine (antitussive and anticancer), and thebaine (precursor for semisynthetic opioids).^[7,8] Simultaneously, it has been a subject of controversy due to narcotic abuse, dependence, and its role in the illicit heroin trade.^[9] From a socio-economic perspective, *P. somniferum* is cultivated legally under strict international control in India, Turkey, Australia, and several other countries for pharmaceutical alkaloid production.^[10,11] Globally, millions of patients rely on morphine and codeine for pain management, especially in oncology and palliative care.^[6] Yet, paradoxically, access remains inequitable—some regions face opioid shortages, while others struggle with an epidemic of misuse.^[9,12] Given this duality, the need for a balanced scientific review that integrates botany, phytochemistry, pharmacology, toxicology, ethnopharmacology, and genomics is paramount. This article aims to provide a comprehensive synthesis, highlighting therapeutic promise, regulatory challenges, and research opportunities.^[13,8]

BOTANY, MORPHOLOGY, CULTIVATION, AND HARVESTING

Taxonomy

Papaver somniferum L. belongs to the family Papaveraceae, order Ranunculales, comprising about 44 genera and 775 species worldwide.^[10] It is taxonomically classified as follows:

Kingdom: Plantae

Order: Ranunculales

Family: Papaveraceae

Genus: *Papaver*

Species: *Papaver somniferum* L.

This species is morphologically and chemically distinct from related *Papaver taxa*, with its unique biosynthesis of morphinan alkaloids.^[6]

Morphology

P. somniferum is an annual herbaceous plant typically ranging from 30–150 cm in height.^[13] The stem is erect, glaucous, and often covered by a waxy coating. Leaves are alternate, sessile, and ovate to oblong, with lobed or toothed margins.^[2] Flowers are large (5–10 cm diameter), borne singly, with four petals varying from white, pink, red to violet, frequently showing dark basal spots. The fruit is a capsule, globular to ovoid (2–5 cm in diameter), dehiscent via apical pores. It contains numerous kidney-shaped seeds that vary in color—white, blue, or black—depending on cultivar.^[3] Specialized laticifers in the capsule wall secrete a white latex, which is the commercial source of crude opium.^[1]

Geographical Distribution

Although native to the Mediterranean basin, *P. somniferum* is now cultivated across Europe, Asia, North Africa, and Oceania.^[10] Major licensed producers include India (notably Madhya Pradesh, Rajasthan, Uttar Pradesh), Turkey, Australia, and parts of Eastern Europe.^[7] The species thrives in cool temperate climates with optimal growth at 10–25 °C and moderate rainfall.^[13] Photoperiod sensitivity and vernalization requirements influence flowering and capsule development.^[6]

Cultivation Practices

Soil: Prefers well-drained loamy soils with pH 6.0–7.5.^[2] Sowing: Seeds are broadcast or line-sown in autumn or early spring, requiring vernalization for optimum yield.^[4] Fertilization: Balanced NPK application increases capsule and latex yield.^[3] Diseases & Pests: The crop is vulnerable to downy mildew (*Peronospora arborescens*), powdery mildew, stem rot (*Sclerotinia* spp.), and pests such as aphids.^[10]

Harvesting

Latex collection occurs 7–10 days after petal fall, when capsules are still unripe.^[13] Shallow incisions are made on the capsule surface, and the exuded latex coagulates overnight. The following day, it is scraped, collected, and dried into crude opium.^[6] Mature capsules,

harvested separately, yield poppy seeds widely used in culinary and oil industries^[4] However, trace alkaloid contamination in seeds remains a food safety concern^[11]

PHYTOCHEMISTRY

Alkaloid Composition

More than 100 alkaloids have been reported in *P. somniferum*, mainly belonging to the benzyloisoquinoline alkaloid (BIA) family^[6,10] The most pharmacologically important groups include: Phenanthrene alkaloids: morphine, codeine, thebaine, oripavine.^[13] Isoquinoline alkaloids: papaverine.^[4] Phthalideisoquinoline alkaloids: noscapine.^[8] Concentrations of these alkaloids vary with genotype, environment, and developmental stage.^[3] Typically: Morphine: 5–20% of latex dry weight, Codeine: 0.5–3%, Thebaine: up to 2% and Noscapine: 2–10%.^[2,11]

Biosynthetic Pathways

Alkaloid biosynthesis begins with L-tyrosine, which yields dopamine and 4-hydroxyphenylacetaldehyde. These condense to form (S)-norcoclaurine, the central precursor of all BIAs.^[14] Enzymatic modifications-including O-methyltransferases, cytochrome P450s, reductases, and transferases-diverge into branch pathways leading to morphinan (morphine, codeine, thebaine), isoquinoline (papaverine), and phthalideisoquinoline (noscapine) alkaloids.^[6,15] Recent genomic and transcriptomic studies have identified biosynthetic gene clusters for morphinan alkaloids, paving the way for metabolic engineering and synthetic biology.^[16,17]

Non-Alkaloid Constituents

Besides alkaloids, *P. somniferum* contains: Phenolics and flavonoids such as catechin, quercetin, and rutin, which contribute to antioxidant activity.^[13] Fatty acids: Poppy seed oil is rich in linoleic acid (~60%) and oleic acid (~30%).^[18] Volatile compounds: Linalool, terpenes, and esters contribute to aroma and may possess antimicrobial potential.^[19]

Analytical Techniques

Modern techniques for alkaloid detection and quantification include: High-performance liquid chromatography (HPLC) with UV or MS detection.^[8] Gas chromatography-mass spectrometry (GC-MS) for volatile and semi-volatile compounds.^[18] Capillary electrophoresis for charged alkaloids.^[19] NMR spectroscopy for structural elucidation of novel constituents.^[16] These approaches enable quality control of raw opium,

pharmaceuticals, and even forensic differentiation between poppy seed ingestion and illicit drug use.^[11]

PHARMACOLOGICAL ACTIVITIES

Analgesic and Anesthetic Effects

Morphine remains the “gold standard” analgesic due to its potent μ -opioid receptor agonism, producing profound central analgesia and sedation.^[6,7] Its clinical applications extend from postoperative pain to palliative oncology care, where it significantly improves quality of life in terminally ill patients.^[12] Codeine, a weaker opioid, exerts antitussive and mild analgesic actions, primarily through hepatic conversion to morphine via CYP2D6 metabolism.^[11,8]

Antitussive Activity

Both codeine and noscapine exhibit antitussive properties, but noscapine is notable for its non-opioid mechanism, lacking respiratory depression or addiction risk.^[13] This makes noscapine a safer alternative in chronic cough therapy, especially in pediatric and geriatric populations.^[15]

Antispasmodic and Vasodilatory Effects

Papaverine, unlike morphine or codeine, is non-opioid and acts as a phosphodiesterase inhibitor, leading to smooth muscle relaxation and vasodilation.^[19] Clinically, papaverine is used in gastrointestinal spasm disorders, cerebral vasospasm, and in erectile dysfunction therapy as an intracavernosal injection.^[10]

Anticancer Potential

Noscapine has emerged as a promising anticancer candidate, functioning by binding tubulin and inhibiting microtubule dynamics.^[8] Preclinical studies have shown noscapine's efficacy against glioblastoma, breast, prostate, and ovarian cancers, with minimal toxicity compared to conventional chemotherapeutics.^[16] Recent clinical trials are exploring its adjunctive use in multidrug regimens.^[17]

Neuroprotective and Antioxidant Effects

Experimental studies indicate that opioid alkaloids such as morphine and codeine exert neuroprotective effects through antioxidant enzyme upregulation and NMDA receptor modulation.^[4] However, chronic use induces tolerance, dependence, and potential neurotoxicity, warranting careful therapeutic regulation.^[9]

Anti-inflammatory Effects

Papaverine and noscapine exhibit mild anti-inflammatory effects, partly via cytokine modulation and suppression of NF- κ B pathways.^[13] Recent *invitro* studies also suggest potential applications in autoimmune disorders, though clinical validation remains pending.^[10]

TOXICITY

Acute Toxicity

Acute toxicity from *Papaver somniferum* derives primarily from its opioid alkaloids (notably morphine and codeine) present in crude opium or concentrated extracts. Clinical features of opioid overdose - the classic “opioid triad” - are respiratory depression, miosis (pinpoint pupils), and reduced consciousness; without prompt intervention these can be fatal due to hypoventilation and hypoxic brain injury.^[9,7] Cardiac arrhythmias and pulmonary edema may occur in severe cases.^[12] Management: Immediate supportive care with airway protection and ventilation is critical. The opioid antagonist naloxone is the first-line antidote; it competitively displaces opioids from μ -receptors and reverses respiratory depression, though multiple or continuous dosing may be necessary for long-acting preparations.^[11,20]

Chronic Toxicity, Dependence, and Withdrawal

Long-term use of opioid-containing preparations leads to tolerance (requiring higher doses for the same effect), physical dependence, and a characteristic withdrawal syndrome on cessation (agitation, myalgias, rhinorrhea, lacrimation, yawning, diarrhea, and insomnia).^[21,9] Chronic opioid exposure also produces adverse systemic effects including constipation and bowel dysfunction, endocrine axis suppression (hypogonadism, decreased libido), immunomodulation, and potential neurocognitive impairment.^[12,21]

Addiction vs. Physical Dependence: Addiction is a behavioral disorder characterized by compulsive drug seeking and use despite harm; physical dependence is a physiological adaptation. Both are relevant to *P. somniferum* derivatives and influence clinical prescribing and regulatory policies.^[9]

Neonatal and Perinatal Effects

Maternal use of opioid-containing drugs can result in neonatal opioid withdrawal syndrome (NOWS), with newborns exhibiting irritability, feeding difficulties, tremors, hypertonia, and autonomic instability.^[12] Prenatal opioid exposure may also be associated with low birth

weight and adverse neurodevelopmental outcomes; management requires multidisciplinary obstetric and neonatal care.^[11]

Toxicokinetics and Drug Interactions

Metabolism: Codeine's analgesic efficacy depends on O-demethylation to morphine via CYP2D6; genetic polymorphisms in CYP2D6 produce poor, intermediate, extensive, or ultra-rapid metabolizers, affecting both efficacy and toxicity risk.^[11,12]

Interactions: Concomitant use with benzodiazepines, alcohol, gabapentinoids, or other respiratory depressants markedly increases the risk of life-threatening respiratory depression.^[9] CYP inhibitors/inducers can alter plasma concentrations of alkaloids and semisynthetic derivatives, necessitating careful dosing.^[21]

Forensic Considerations and Poppy-Seed Testing

Consumption of poppy seeds (culinary use) may yield detectable morphine/codeine in biological samples and produce low-level positive immunoassay screens, complicating forensic interpretation. Differentiating dietary exposure from illicit ingestion relies on quantitative testing, metabolite profiles, and contextual information (e.g., timing of ingestion).^[22,11] Forensic toxicologists frequently use confirmatory GC-MS or LC-MS/MS assays and evaluate ratios of parent drug to metabolites to infer recent illicit use.^[22]

Organ Toxicities and Long-Term Health Effects

Gastrointestinal: Opioids cause dose-dependent reductions in gut motility, leading to constipation, bowel distention, and in severe cases paralytic ileus. Chronic opioid-induced bowel dysfunction impacts quality of life substantially.^[13]

Endocrine: Long-term opioid therapy suppresses the hypothalamic-pituitary-gonadal (HPG) and hypothalamic-pituitary-adrenal (HPA) axes, resulting in hypogonadism, decreased bone density, and metabolic consequences.^[12]

Immune Function: Experimental data indicate opioids can modulate immune responses, though clinical implications for infection risk remain incompletely defined.^[21]

Special Populations and Safety Concerns

Elderly: Increased sensitivity to respiratory depressant effects and altered pharmacokinetics require lower starting doses and cautious titration.

Children: Codeine use in children is restricted in many jurisdictions due to variable CYP2D6 metabolism and risk of fatal respiratory depression; safer alternatives are recommended.^[11]

Patients with Pulmonary Disease: Chronic obstructive pulmonary disease (COPD) or sleep apnea increase overdose risk and necessitate extreme caution.^[9]

Regulation, Control, and Risk-Mitigation Strategies

Because *P. somniferum* yields controlled narcotic substances, cultivation, processing, and distribution are subject to stringent international and national controls.^[24]

Risk-mitigation strategies to balance access and minimize harm include: Prescription monitoring programs and controlled dispensing, Use of opioid-sparing multimodal analgesia, Naloxone distribution programs for at-risk patients and community responders. Development and cultivation of low-alkaloid poppy cultivars or biosynthetic production routes to decouple medicinal supply from diversion risks.^[17,11]

GENOMICS AND MOLECULAR BIOLOGY OF *PAPAVER SOMNIFERUM*

Genome Sequencing

The *P. somniferum* genome was sequenced in 2018, revealing a genome size of approximately 2.7 Gb with ~51,000 predicted protein-coding genes.^[23] This genome encodes the entire biosynthetic machinery for benzyloisoquinoline alkaloids (BIAs), including morphine, codeine, thebaine, papaverine, and noscapine. Genome annotation revealed extensive gene duplication events, likely contributing to the diversity of alkaloid biosynthesis in different cultivars.^[23,17]

Biosynthetic Gene Clusters

The genome analysis identified 10–12 gene clusters responsible for BIA synthesis.^[15,16] Key features include: Morphinan cluster: Enzymes like salutaridine synthase (SalSyn), thebaine 6-O-demethylase (T6ODM), codeinone reductase (COR); orchestrates conversion from (S)-reticuline to morphine and codeine.^[16] Noscapine cluster: Ten genes tightly co-located, including coclaurine N-methyltransferase (CNMT), noscapine synthase, enabling phthalideisoquinoline biosynthesis.^[15] Papaverine biosynthesis: Involves isoquinoline-specific methyltransferases and oxidases, largely mapped but not fully clustered.^[14] Gene clustering facilitates coordinated transcription, and transcriptomic studies show that these clusters are highly expressed in capsule tissues during latex production.^[6]

CRISPR/Cas9 and Genetic Engineering

Advances in genome editing allow targeted manipulation of alkaloid biosynthesis: Thebaine reduction: CRISPR/Cas9-mediated knockout of key thebaine biosynthetic genes produces low-thebaine, low-morphine poppy cultivars, suitable for safer cultivation and pharmaceutical production.^[17]

Alkaloid pathway elucidation: Knockout or overexpression of methyltransferases or oxidases confirms rate-limiting steps and enables engineering for enhanced yield of non-narcotic alkaloids like noscapine.^[16]

Metabolic flux optimization: Combinatorial gene editing and promoter engineering increase flux toward desired alkaloids while reducing toxic intermediates.^[6]

Synthetic Biology and Microbial Production

Synthetic biology approaches aim to reconstruct morphinan pathways in microbes, reducing reliance on field-grown poppy plants:

Yeast-based systems: Reconstitution of the morphinan pathway in *Saccharomyces cerevisiae* enables production of thebaine and hydrocodone under controlled fermentation.^[17]

Advantages: Reduces environmental dependency, circumvents narcotic diversion, allows scalable production, and supports semi-synthetic derivatization for novel analgesics.^[15]

Challenges: Complex pathway enzymes require precise subcellular targeting, cofactor availability, and regulatory optimization to achieve commercially viable yields.^[16]

Future Directions in Genomics

Functional genomics: Transcriptomics, proteomics, and metabolomics integration to identify novel regulators of alkaloid biosynthesis.

Precision breeding: Marker-assisted selection and gene editing to develop cultivars with tailored alkaloid profiles for medicinal vs. industrial purposes.

Synthetic biology expansion: Multi-organism consortia to reconstruct complete BIA pathways, enabling safer, high-yield, and non-narcotic production platforms.

Regulatory genomics: Utilizing molecular markers to certify legal cultivars and prevent illicit diversion.^[17,6]

FUTURE PROSPECTS

Papaver somniferum continues to be a source of both therapeutic promise and research opportunities. Modern advances in pharmacology, genomics, synthetic biology, and nanomedicine suggest several directions for future exploration:

Drug Discovery and Development

Semi-synthetic derivatives of noscapine and papaverine are being investigated as anticancer agents, vasodilators, and neuroprotective compounds.^[8,13] Structure–activity relationship (SAR) studies can optimize efficacy and minimize adverse effects, particularly for non-opioid alkaloids.

Synthetic Biology and Microbial Production

Microbial reconstitution of morphinan pathways allows controlled, scalable, and diversion-free production of opioids and intermediates.^[17] Engineering yeast or bacterial systems can generate designer alkaloids, enhancing therapeutic diversity and reducing dependence on agricultural cultivation.

Nanomedicine and Targeted Drug Delivery

Opioid and non-opioid alkaloids can be encapsulated in nanocarriers to enable targeted delivery, reduced systemic toxicity, and prolonged action.^[6] This approach may allow lower doses of morphine, reducing addiction potential while maintaining analgesia.

Public Health and Access Optimization

Balancing access to essential pain medications with strategies to prevent abuse and diversion remains critical.^[11] Low-alkaloid cultivars, precision medicine approaches, and prescription monitoring programs can reduce opioid-related morbidity while ensuring availability for legitimate medical use.

Regulatory and Ethical Considerations

Development of non-narcotic high-value poppy cultivars is an emerging focus for pharmaceutical and nutraceutical applications. International collaboration and legal frameworks are required to facilitate research, ensure ethical use, and monitor environmental and societal impact.^[24,17]

CONCLUSION

Papaver somniferum represents a paradoxical plant—at once a blessing for pain relief and a curse due to narcotic abuse. Its alkaloids remain essential medicines, while non-narcotic constituents like noscapine and papaverine hold untapped therapeutic promise. Bridging ethnomedicine, phytochemistry, molecular biology, and pharmacology, future research must emphasize clinical validation, safe biotechnological production, and strict but equitable regulatory frameworks.

ACKNOWLEDGEMENT

The authors sincerely acknowledge the PG and Research Department of Biochemistry, D.G. Govt. Arts College for Women, Mayiladuthurai, for providing the necessary facilities, guidance, and support to carry out this research work successfully. The authors also express their gratitude to the Principal and all faculty members of the Department for their constant encouragement and valuable assistance throughout the study.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

REFERENCES

1. Porter M. The History of Opium: From Antiquity to Addiction. London: Br Med Libr Press, 1999.
2. Sharma R. Medicinal Plants of India. New Delhi: Daya Publ House, 2005.
3. Khan A. Medicinal and Aromatic Plants of the World. New Delhi: Anmol Publ., 2008.
4. Li SH, Zhang H, Wang Z. Traditional use of *Papaver somniferum* in ancient and medieval medicine. J Ethnopharmacol, 2012; 142(2): 585–593.
5. Serturner FWA. Ueber das Morphinum, eine neue salzfähige Grundlage des Opiums. J Pharm Ärzte Apotheker, 1805; 13: 229–243.
6. Gupta S, Patel P, Sharma R. Pharmacognostic and pharmacological profile of *Papaver somniferum* L. (opium poppy): A comprehensive review. Int J Pharm Sci Res., 2020; 11(2): 512–530
7. World Health Organization (WHO). Model List of Essential Medicines – 21st List. Geneva: WHO, 2019.
8. Zhou Y, Tang H, Wang X, Chen J. Pharmacological effects of opium alkaloids and their derivatives. Front Pharmacol, 2019; 10: 743.

9. National Institute on Drug Abuse (NIDA). Opioid Overdose Crisis: Annual Report. Bethesda (MD): NIH; 2020.
10. Smith J, Brown R, Patel K. The opium poppy: Cultivation, chemistry and regulation. *J Nat Prod.*, 2017; 80(10): 2591–2605.
11. World Health Organization (WHO). Guidelines for the Management of Opioid Use and Dependence. Geneva: WHO, 2022.
12. Johnson RE, Fudala PJ, Payne R. Opioid pharmacology and management of opioid dependence. *N Engl J Med.*, 2015; 373(22): 2137–2147.
13. Patel D, Desai S, Vyas R. Pharmacological and phytochemical overview of *Papaver somniferum* L. *Asian J Pharm Clin Res.*, 2018; 11(3): 45–52.
14. Facchini PJ, De Luca V. Opium poppy and Madagascar periwinkle: Model non-model systems to investigate alkaloid biosynthesis in plants. *Plant J.*, 2008; 54(4): 763–784.
15. Winzer T, Gazda V, He Z, Kaminski F, Kern M, Larson TR, Graham IA. A *Papaver somniferum* 10-gene cluster for synthesis of the anticancer alkaloid noscapine. *Science.*, 2012; 336(6089): 1704–1708.
16. Beaudoin GAW, Facchini PJ. Benzyloquinoline alkaloid biosynthesis in opium poppy: An update. *Phytochem Rev.*, 2014; 13(1): 69–84.
17. Yang X, Guo L, Li Y, Graham IA. Engineering morphinan biosynthesis in yeast: Progress and prospects. *Nat Commun*, 2021; 12(1): 514.
18. Ahuja A, Kumar A, Singh R. Composition and properties of poppy seed oil. *J Food Sci Technol.*, 2010; 47(3): 295–298.
19. Kumar P, Singh V, Sharma N. Phytochemical and pharmacological evaluation of *Papaver somniferum* L. *Int J Pharm Pharm Sci.*, 2016; 8(10): 76–82.
20. Strang J, McDonald R, Alqurshi A. Naloxone: An antidote for opioid overdose. *Drug Alcohol Depend.*, 2019; 204: 107–124.
21. Kreek MJ, Levran O, Reed B, Schlussman SD, Zhou Y, Butelman ER. Opiate addiction and stress response: An overview. *Psychoneuroendocrinology*, 2012; 37(9): 1236–1248.
22. Cone EJ. Forensic drug testing for opiates: Understanding poppy seed ingestion and legal implications. *J Anal Toxicol*, 2015; 39(7): 497–501.
23. Guo L, Winzer T, Yang X, Li Y, Ning Z, He Z, Graham IA. The opium poppy genome and morphinan production. *Science*, 2018; 362(6412): 343–347.
24. United Nations. Single Convention on Narcotic Drugs, 1961. New York: United Nations, 1961.